Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor
Open Access
- 12 January 2017
- journal article
- Published by American Society of Hematology in Blood
- Vol. 129 (2), 257-260
- https://doi.org/10.1182/blood-2016-10-745133
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaNew England Journal of Medicine, 2013
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemiaNature, 2012
- Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencingNature, 2012
- Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapseBlood, 2011
- Phase I study of sorafenib in patients with refractory or relapsed acute leukemiasHaematologica, 2010
- FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AMLBlood, 2010
- Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitorsBritish Journal of Cancer, 2009
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)Blood, 2009
- A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical responseBlood, 2009
- Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitorsBlood, 2006